JP Morgan Week 2025 - Marianne De Backer

Vir Biotechnology, a company focused on activating the immune system to treat a variety of conditions in cancer and infectious disease, came into JP Morgan with promising safety and efficacy data for two dual-masked T Cell engagers, VIR-5818 for HER2-positive breast cancer and VIR-5500 in prostate cancer, both licensed from Sanofi.
At the conference last week in San Francisco, pharmaphorum Editor in Chief Jonah Comstock spoke with Vir Biotechnology CEO Marianne De Backer, who explained a bit more about what a dual-masked T Cell engager is and why they are so promising at mitigating the toxicity of previously attempted TCEs.
They also discuss De Backer’s thoughts about the shifting political environment in the United States and what it might mean for pharma. And De Backer shares the company’s next steps and their search for commercial partners for new applications of the T Cell masking platform.
Check out the video below to learn more, and stay tuned for more video interviews from JP Morgan Week 2025.